Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2399-2411

  Munoz, Jessian L ^a   Rodriguez Cruz, Vivian ^b   Greco, Steven J ^a   Nagula, Vipul ^a   Scotto, Kathleen W ^c   Rameshwar, Pranela ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PUERTO RICO AT CAYEY   (Puerto Rico)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN C FOS; PROTEIN C JUN; SMALL INTERFERING RNA; TEMOZOLOMIDE; ABCB1 PROTEIN, HUMAN; ALKYLATING AGENT; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; IC50; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR VOLUME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED BALB C; P-GLYCOPROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921787861     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0011     Document Type: Article

References (30)

1. Ohka F, Natsume A, Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int 2012;2012:878425.
2. Perry J, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A. Novel therapies in glioblastoma. Neurol Res Int 2012;2012:428565.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
4. Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 2007;55:1-15.
5. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003;22:7496-511.
6. van Groenigen M, Valentijn LJ, Baas F. Identification of a functional initiator sequence in the human MDR1 promoter. Biochim Biophys Acta 1993;1172:138-46.
7. Chen GK, Sale S, Tan T, Ermoian RP, Sikic BI. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 2004;65:906-16.
8. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 2000;3:268-80.
9. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999;5:3352-6.
10. Witte M, Dellinger M, Papendieck C, Boccardo F. Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia. Clin Exp Metastasis 2012;29:707-27.
11. Mimeault M, Batra SK. Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 2010;62:497-524.
12. Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P, et al. Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features. Neuropathol 2010;30:392-400.
13. Heimberger A, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005;3:38.
14. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010;9:135.
15. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids 2013;2:e126.
16. Gramatzki D, Herrmann C, Happold C, Becker KA, Gulbins E, Weller M, et al. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS ONE 2013;8:e63527.
17. Jin S, Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998;18:4377-84.
18. Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 2011;71:1550-60.
19. Park JM, Munoz JL, Won BW, Bliss SA, Greco SJ, Patel SA, et al. Exogenous CXCL12 activates protein kinase C to phosphorylate connexin 43 for gap junctional intercellular communication among confluent breast cancer cells. Cancer Lett 2013;331:84-91.
20. Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med 2011;17:103-12.
21. Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004;15:503-12.
22. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 2009;11:281-91.
23. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 2009;20:175-81.
24. Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, et al. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 2002;98:173-80.
25. Fu D, Arias IM. Intracellular trafficking of P-glycoprotein. Intl J Biochem Cell Biol 2012;44:461-4.
26. Blau L, Knirsh R, Ben-Dror I, Oren S, Kuphal S, Hau P, et al. Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation. Proc Natl Acad Sci 2012;109:E2875-84.
27. Ye Y, Wang D, Su C, Rong T, Guo A. Combined detection of p53, p16, Rb, and EGFR mutations in lung cancer by suspension microarray. Genet Mol Res 2009;8:1509-18.
28. Dolghih E, Bryant C, Renslo AR, Jacobson MP. Predicting binding to Pglycoprotein by flexible receptor docking. PLoS Comput Biol 2011;7:e1002083.
29. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, et al. De-repression of PDGFR beta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013;3:534-47.
30. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.